CerebrolysinNeurotrophic Peptide MixtureBlendSafety Rating 6/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors
Overview
About Cerebrolysin
Mechanism of action
Mixture of low molecular weight neuropeptides and amino acids; mimics neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis, synaptogenesis, and neuroprotection; BBB-penetrant.
Safety profile
Injection site reactions; dizziness; agitation with high doses; rare allergic reactions. Very well-studied with good long-term safety data. · Used in Europe/Asia for stroke/TBI; some clinical trial data; not FDA-approved but prescribed widely abroad
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Cerebrolysin below your target.
Related pages
More on Cerebrolysin
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Cerebrolysin is a standardized porcine brain-derived peptide mixture containing low-molecular-weight neuropeptides with BDNF-like and NGF-like activity; it is widely approved and used in Russia, Eastern Europe, China, and parts of Asia for stroke, vascular dementia, and Alzheimer's disease, though it lacks full regulatory approval in the US and Western Europe.
- A 2016 randomized Phase II trial (CARS) in acute ischemic stroke patients found Cerebrolysin produced significantly better upper extremity motor recovery than placebo at 90 days (effect size 0.71, p<0.0001); a 2018 meta-analysis of nine RCTs confirmed statistically significant neurological improvement at 30 days, with a number needed to treat of approximately 8.